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Aim: The study was made to evaluate early and late toxicity in a diversiﬁed group of patients
receiving deﬁnitive or adjuvant radiotherapy in terms of clinical diagnosis and treatment
methods.
Background: Radiotherapy is a standard way of treatment in cervical and endometrial cancer
patients, both as deﬁnitive and adjuvant therapy. But every radiation treatment may be
involved with toxicity.
Materials and methods: A detailed analysis was performed of 263 patients with gynaecological
cancer treated with deﬁnitive (90 patients with cervical cancer received radiochemother-
apy or radiotherapy exclusively) and adjuvant radiotherapy (38 with cervical and 135 with
endometrial cancer).
Results: Acute reactions were found in 51.3% and late reactions were found in 14.8% of
patients. It was stated that early (p < 0.007) and late (p < 0.003) post radiation reaction appear
more  frequently in women treated with deﬁnitive than adjuvant radiotherapy. The analysis
of  the whole group revealed higher rate of toxicity, both early and late, in the gastrointesti-
nal tract than in the urinary system (p < 0.004). Comparing the subgroups, it was found that
intestinal reactions occurred more frequently in the deﬁnitive radiotherapy group than inthe  adjuvant one.
The occurrence of side effects was associated with the prolongation of total irradiationtime due to necessary interruptions of radiotherapy. The comparison of the subgroups
showed that interruptions occurred more frequently in patients receiving deﬁnitive rather
than adjuvant radiotherapy (17.7–2.9%).
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Conclusions: Deﬁnitive radiotherapy compared with adjuvant treatment may by associated
with higher percentage of side effects caused by dose of therapy and correlation with
chemotherapy.
©  2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
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2. Background
ndometrial cancer is the fourth most frequent type of cancer
ffecting women in Poland, following breast, lung and colon
ancers, while cervical cancer is right behind it.1 Radiotherapy,
longside with surgery and chemotherapy, is an important
art of the therapeutic process in women suffering from these
ancers. Irradiation of the pelvis is the key component of a
eﬁnitive or adjuvant treatment of cervical and endometrial
ancer patients. The planning target volume (PTV), apart from
he target itself (tumour or bed after excision of the tumour
nd the lymph nodes), comprises a number of healthy struc-
ures and organs, including the intestines and bladder. These
rgans, both during and after irradiation, are affected with
arly and late toxicity associated with destructive activity of
onising radiation. In many  studies, authors have underlined
hat around 50% of patients irradiated to the pelvis exhibit
adiation toxicity during radiotherapy.2–5 It is associated with
 treatment method (radical radiotherapy including in com-
ination with chemotherapy or adjuvant radiotherapy) and
adiation dose (combining teleradiotherapy and brachyther-
py). Analysing radiation toxicity in relation to varied and ever
hanging treatment methods is as important as it is difﬁcult.
.  Aim
he aim of this study is to analyse early and late radiation
ffects in a diversiﬁed group of patients receiving both deﬁni-
ive and adjuvant radiotherapy in terms of clinical diagnosis
nd treatment methods.
.  Materials  and  methods
.1.  Patients  and  treatment
he study covered 263 cervical cancer (CC) and endome-
rial cancer (EC) patients receiving deﬁnitive or adjuvant
adiotherapy at the Radiotherapy and Gynecologic Oncol-
gy Department of the Greater Poland Cancer Centre. The
ecruitment process took 12 months, from May 2006. Due to
ifferent diagnosis (CC and EC) and different treatment meth-
ds (deﬁnitive or adjuvant radiotherapy), the patients were
ivided into two subgroups that were compared both inter-
ally and with each other.
The ﬁrst subgroup consisted of 90 women with diagnosed
IGO stage IIB and IIIB cancer of the cervix treated with radical
adiotherapy (radiotherapy exclusively or radiochemother-
py). All analysed patients received both external-beam
adiation therapy (EBRT) and brachytherapy (BRT). Of them,
9 were managed with radiotherapy (RT) only, the other 61rights reserved.
were given radiochemotherapy (RCHT) – cisplatin at 40 mg/m2
administered once a week over the radiotherapy period.
The RT patients had not been qualiﬁed for combined treat-
ment (RCHT) not only because of their old age (they tended to
be older than RCHT patients), but also due to concomitant dis-
eases, such as kidney failure induced by advanced neoplasm.
External conformal radiotherapy was performed using four
beams controlled by leaves of a multi-leaf collimator. Clinical
target volume (CTV) comprised the tumour of the cervix along
with the corpus uteri, vaginal wall and fornix, parametrium
and lymph nodes of the pelvis. Fractionation dose was 1.8 Gy
given 5 times a week. In the area of higher dose of LDR
brachytherapy (BRT LDR), a central shield was used during
teleradiotherapy assuming an ICRU-compliant dose of 85 Gy
to point A. The correctness of teleradiotherapy was evalu-
ated with portal images and in vivo dosimetry. In the case of
brachytherapy, both physical and biological doses (EQD2) were
measured.
An average EBRT dose in this group of patients was
48.2 Gy (range 12.6–54 Gy); an average BRT LDR dose was
44 Gy (20–60 Gy). In the group treated with HDR  brachyther-
apy, patients received 28 Gy in 4 fractions and a total external
beam dose of 45 Gy/T. For the IIIB stage patients, an external
beam dose to the parametrium was increased to 50.4 Gy/T.
The other subgroup consisted of 173 patients receiving an
adjuvant radiotherapy following surgery for FIGO stage IB-IIA
cervical cancer (38 patients) and FIGO stage I-IIIA endometrial
cancer (135 patients). Qualiﬁed to the adjuvant radiothe-
rapy group were patients with poor prognostic factors from
histopathological tests.
Conformal external-beam radiotherapy, as in the case
of deﬁnitive radiotherapy, was delivered using four beams
controlled by leaves of a multileaf collimator; 15 patients
were treated with inter modulate radiation therapy (IMRT).
The target volume included the lymph nodes of the pelvis.
The fractionation dose was 1.8 Gy delivered 5 times a week.
Total average dose to the planning target volume was
43.4 Gy/T ± 5 Gy.
All the patients received high dose rate (HDR) brachyther-
apy – 3 fractions of 6.0 Gy each, administered weekly.
The dose was ﬁxed at 0.5 cm from the applicator surface,
its diameter adjusted to the anatomy of patient’s vagina
(2.0–4.0 cm).
3.2.  Methodology
The patients were observed prospectively in the course of
treatment (evaluations were made weekly) and at control
examinations during a two-year follow-up. They were ana-
lysed for general health status, laboratory test results and
radiation reactions from the intestines and urinary system.
The analysis related to the course of radiotherapy, including
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Table 1 – Analysis of radiotherapy interruption of more  than 7 days in both subgroups.
Treatment method
Number and % of patients
Cause of interruption Location of toxicity (number and % of patients)
Bladder Intestines
Deﬁnitive radiotherapy
16 (17.7%)
3  (18.8%) 13 (81.2%)
Adjuvant radiotherapy 0  (0%) 5 (100%)
highest (36.9%) in patients with cervical cancer (CC) receiv-5 (2.9%)
interruptions in radiotherapy. The radiotherapy was evaluated
based on medical documentation and irradiation sheets.
Subject to investigation was both early and late toxicity (occur-
ring later than 90 days after radiotherapy) observed during a
two-year follow-up. In order to achieve the aim of the study,
that is to evaluate radiation toxicity, the EORTC/RTOG scale
was used. In further analysis, grade 1 and 2 reactions were
collectively rated as mild, while grade 3 and 4 reactions were
rated as severe.
The statistical analysis was carried out using the Chi-
square, Mann–Whitney U, and Fisher’s tests. The study
employed FIGO classiﬁcation applicable at that time, before
the modiﬁcation of 2009.
4.  Results
4.1.  Analysis  of  the  whole  studied  group  and
comparison  of  selected  subgroups
Early toxicity was found in 51.3% of all analysed patients. It
occurred more  often in the deﬁnitive radiotherapy group (27%),
than in the adjuvant radiotherapy group (24.3%); the difference
being statistically signiﬁcant (p < 0.007).
Late toxicity occurred in 14.8% of patients, including 9.9%
of those treated with deﬁnitive radiotherapy and 4.9% treated
with adjuvant radiotherapy. Just like for early toxicity, the dif-
ference was statistically signiﬁcant (p < 0.006).
The analysis of the whole studied group (263 patients)
revealed higher rate of toxicity, both early and late, in the
gastrointestinal tract than the urinary system (p < 0.004). Com-
paring the subgroups, it was found that intestinal reactions
occurred more  frequently in the deﬁnitive radiotherapy group
than in the adjuvant radiotherapy group.
Analysing the subgroup of cervical cancer patients treated
with deﬁnitive radiotherapy, it was found that patients
given radiotherapy exclusively were statistically signiﬁcantly
older than those receiving radiochemotherapy. The mean age
of patients treated with radiotherapy was 64.6 years ± 11.3
versus 51.6 years ± 8.5 for those treated with radiochemother-
apy.
In the adjuvant radiotherapy group, patients with endome-
trial cancer were statistically signiﬁcantly older than those
with cervical cancer (p < 0.002). The mean age of patients
with diagnosed cancer of the endometrial was 64.9 years ± 8.2
versus 54.0 years ± 8.7 for patients with cancer of the
cervix.
The occurrence of side effects was associated with the
prolongation of total irradiation time due to necessaryinterruptions of radiotherapy, including longer than seven
days. This applied mostly to older patients in both subgroups
(deﬁnitive and adjuvant radiotherapy). The comparison of
the subgroups showed that interruptions occurred more  fre-
quently in patients receiving deﬁnitive radiotherapy than in
those treated with adjuvant radiotherapy (17.7% and 2.9%,
respectively) – see Table 1. These were mainly caused by
intestinal toxicity.
Analysing radiotherapy interruptions of more  than seven
days, it was found that in the deﬁnitive radiotherapy sub-
group the interruptions were correlated with a treatment
method, occurring more  often in patients treated with RT
than in those treated with RCHT (10.0% and 7.7%, respec-
tively). In the adjuvant radiotherapy subgroup, the incidence
of radiation toxicity correlated with clinical diagnosis, with
endometrial cancer patients showing more  frequent therapy
interruptions than cervical cancer patients (2.3% and 0.6%,
respectively)
4.2. Evaluation  of  early  radiation  toxicity
The rate of early radiation toxicity was higher in the intestines
than in the bladder (33.1% and 22.1%, respectively, for all
patients).
Data regarding early radiation effects were presented inde-
pendently for the intestines and the bladder broken down
into four subgroups: deﬁnitive radiotherapy (cervical patients
treated with RT or RCHT) and adjuvant radiotherapy (patients
with CC and EC).
Shown below is the analysis of early toxicity in the gas-
trointestinal tract. Results are presented in Table 2.
The highest rate of intestinal toxicity was recorded in cervi-
cal cancer patients receiving deﬁnitive radiotherapy, of which
65.5% were treated with RT and 37.7% with RCHT. Of note is a
high percentage of patients with severe complications (grades
3 and 4). These were also patients managed with deﬁnitive
radiotherapy (24.1% in the RT group and 26.2% in the RCHT
group). Intestinal reactions occurred much less often after
adjuvant therapy.
Analogous analysis was made for early toxicity in the blad-
der. Results are shown in Table 3.
Notably, early radiation toxicity in the bladder was less
frequent than that in the intestines, its incidence being theing adjuvant radiotherapy after surgery. In the same subgroup,
aside from cervical cancer patients treated with RT, the anal-
ysis showed a relatively high proportions of severe effects, i.e.
8.0% and 10.4%, respectively.
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Table 2 – Early radiation intestinal toxicity in the intestines in patients receiving deﬁnitive (RCHT and RT) and adjuvant
(CC and EC) radiotherapy – EORTC scale.
Treatment method/clinical diagnosis
Number of patients (toxicity rate)
Toxicity grade (number and % of patients)
Grade 0 Grades 1 and 2 Grades 3 and 4
RCHT 61 (37.7%) 38 (62.3%) 7 (11.5%) 16 (26.2%)
RT 29 (65.5%) 10 (34.5%) 12 (41.4%) 7 (24.1%)
CC 38 (23.7%) 29 (76.3%) 6 (15.8%) 3 (7.9%)
EC 135 (26.7%) 99 (73.3%) 24 (17.8%) 12 (8.9%)
Table 3 – Early radiation toxicity from the bladder in patients receiving deﬁnitive (RCHT and RT) and adjuvant (CC and CE)
radiotherapy – EORTC scale.
Treatment method/clinical diagnosis
Number of patients (toxicity rate)
Toxicity grade (number and % of patients)
Grade 0 Grades 1 and 2 Grades 3 and 4
RCHT 61 (21.3%) 48 (78.7%) 9 (14.7%) 4 (6.6%)
RT 29 (20.8%) 23 (79.2%) 3 (10.4%) 3 (10.4%)
CC 135 (36.9%) 24 (63.1%) 11 (28.9%) 3 (8.0%)
EC 135 (18.5%) 110 (81.5%) 23 (17.0%) 2 (1.5%)
Table 4 – Late intestinal toxicity in patients receiving deﬁnitive (RCHT and RT) and adjuvant radiotherapy (CC and EC),
EORTC scale.
Treatment method/clinical diagnosis
Number of patients (toxicity rate)
Toxicity grade (number and % of patients)
Grade 0 Grades 1 and 2 Grades 3 and 4
RCHT 61 (21.3%) 48 (78.7%) 11 (18%) 2 (3.3%)
RT 29 (27.6%) 21 (72.4%) 7 (24.2%) 1 (3.4%)
CC 38 (10.5%) 34 (89.5%) 4 (10.5%) 0 (0.0%)
EC 135 (7.4%) 125 (92.6%) 10 (7.4%) 0 (0.0%)
Table 5 – Late radiation toxicity in the bladder in patients receiving deﬁnitive (RCHT and RT) and adjuvant radiotherapy
(CC and EC), EORTC scale.
Treatment method/clinical diagnosis
Number of patients (toxicity rate)
Toxicity grade (number and % of patients)
Grade 0 Grades 1 and 2 Grades 3 and 4
6.5% juice 57 (93.5%) 4 (6.5%) 0 (0.0%)
RT (3.4%) 26 (96.6%) 1 (3.4%) 0 (0.0%)
CC (2.6%) 37 (97.4%) 1 (2.6%) 0 (0.0%)
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.3.  Evaluation  of  late  radiation  toxicity
nalysis results for late toxicity, as in the case of early toxicity,
ndicate higher incidence in the intestines than in the bladder
13.3% and 3.0%, respectively).
The results, as those for early toxicity, were presented sepa-
ately for the intestines and the bladder and broken down into
our subgroups: stand-alone radiotherapy (cervical patients
reated with RT or RCHT) and adjuvant radiotherapy (patients
ith CC and EC).
Analysis results for late intestinal toxicity are shown in
able 4.
Of note is a low proportion of patients with severe late reac-ions. These were cervical cancer patients treated with radical
rradiation (3.3% RCHT, 3.4% RT). No severe reactions were
ound in patients who  had underwent adjuvant radiotherapy.
Below is the analysis of late toxicity in the bladder (Table 5).2 (1.5%) 0 (0.0%)
Late radiation toxicity, in low grade only (1 and 2), occurred
in several percent of patients.
5.  Conclusion  and  discussion
5.1.  Conclusion
1. Deﬁnitive radiotherapy, as compared to adjuvant radiothe-
rapy, is associated with signiﬁcantly higher incidence of
early (27% and 24.3%, respectively) and late (9.9% and 4.8%,
respectively) toxicity.2. The whole studied group revealed a statistically signiﬁ-
cantly higher rate of radiation toxicity, both early and late,
in the gastrointestinal tract as compared with the bladder
(61% and 39%) – (p < 0.004).
d rad336  reports of practical oncology an
3. Radiotherapy alone (both RT and RCHT) more  often than
adjuvant radiotherapy related to early and late radiation
toxicity, including severe (grades 3 and 4) and intestinal
complications (p < 0.008).
4. Early toxicity of the bladder was most prevalent in cervical
cancer patients who had been treated with surgery.
5. Interruptions in radiotherapy of more  than 7 days, caused
by the occurrence of adverse radiation effects, were more
often found in patients treated with radiotherapy alone
(17.7%) than adjuvant radiotherapy (2.9%). This led to the
prolongation of total treatment time in those patients.
5.2.  Discussion
The aim of this study was to analyse the incidence of
radiation side effects in cervical and endometrial cancer
patients treated with various radiotherapy methods, includ-
ing in combination with surgery (adjuvant radiotherapy) and
chemotherapy (radiochemotherapy).
Early radiation toxicity (during and within 3 months after
irradiation) occurred in 51.3% of all the analysed patients
versus 14.8% of late toxicity. Similar results for compa-
rable cervical and endometrial cancer groups have been
reported in many  publications analysing deﬁnitive and adju-
vant radiotherapy.2–7,33,36
The analysis of patients managed in the Greater Poland
Cancer Centre showed that a statistically higher percentage
of patients who had developed both early and late radia-
tion toxicity had received a stand-alone rather than adjuvant
radiotherapy (p < 0.007 and p < 0.006). This should be associ-
ated with a higher physical and biological dose delivered to
those patients’ organs at risk. A higher dose to critical organs
in this group of patients resulted from a higher dose to the
parametrium in deﬁnitive external-beam radiation (by 5.4 Gy),
as compared to patients treated with adjuvant radiotherapy,
and from its being combined with LDR or HDR brachytherapy
where doses were higher than in postoperative brachytherapy.
The relationship between high dose and the risk of radia-
tion toxicity during radiotherapy has been pointed out by
such authors as Perez et al.,8 Montana et al.,9 Kootmeier10
and Roszak et al.35 All of them have observed complications
increasing with higher radiation doses.
The whole studied group of 263 patients, regardless of
radiotherapy method used, revealed a statistically signiﬁ-
cantly higher rate of radiation toxicity, both early and rate,
in the gastrointestinal tract than in the bladder (p < 0.004).
This should be accounted for by a lower tolerance dose of
the intestines,37 as compared to the bladder, a large volume
of intestines covered by high dose irradiation, and patients’
difﬁculties in maintaining their indicated nutrition regime.
These factors were also highlighted in the study by Morris
et al. analysing the occurrence of radiation toxicity in patients
receiving radiation to the pelvic ﬁeld.11 Gastrointestinal toxic-
ity was also the main reason for interruptions in radiotherapy
in patients undergoing both radical and adjuvant treatment.
Age is another factor that may have affected treatment tol-
erance. The analysis made in this study showed statistically
signiﬁcant age differences between the two subgroups. Older
patients had higher rate of complications. These results areiotherapy 1 7 ( 2 0 1 2 ) 332–338
consistent with those reported by Lanciano et al.,12,13 where
patients of 40 years and older where proved to develop higher
toxicity.
In the deﬁnitive radiation therapy group, patients receiv-
ing radiotherapy only were statistically signiﬁcantly older
(p < 0.01) and it was them who showed more  complica-
tions, whether early or late. In the adjuvant radiation group,
endometrial cancer patients were statistically signiﬁcantly
older than cervical cancer patients (p < 0.002). The former were
more  frequently observed to develop concomitant diseases,
such as hypertension, diabetes, asthma and obesity. The addi-
tional diseases and older age caused reactions occurring in
these patients, even though less frequent during radiothe-
rapy, to be more  often of the type requiring radiotherapy to
be interrupted for more  than 7 days.
Analysing tolerance-related treatment interruptions, it
was found that interruptions lasting more  than 7 days
occurred more  often in patients treated with radiotherapy only
than in those treated with adjuvant radiotherapy (17.7% and
2.9%, respectively). The interruptions led to the prolongation
of total treatment time.
The toxicity analysis of both subgroups showed that out
of all cervical patients treated with deﬁnitive radiotherapy,
those receiving radiotherapy only had higher rate of com-
plications, both early and late, as compared with patients
receiving radiochemotherapy. These results differ from pub-
lished reports. The NCIC study14 found no difference in the
occurrence of early and late radiation toxicity in two patients
groups: those receiving radiochemotherapy and radiotherapy
alone. Other authors, however, indicate an adverse effects of
concurrent chemotherapy.11 Results of our analysis may be
related to our patients’ high clinical stage of the disease; con-
currence of renal failures and other diseases; as well as old
age disqualifying them from radiochemotherapy.
It should be stressed that, despite higher gastrointestinal
toxicity in the group treated with RT alone, severe complica-
tions occurred more  frequently in patients receiving combined
radiotherapy and chemotherapy, which may be related to the
joint, synergistic activity of both modalities. The combination
of two toxic factors leads to the increase in the rate of adverse
reactions. This correlation has also been indicated by the
authors of RTOG 90-01.5 This effect, on one hand favourable in
combating neoplastic cells, turns undesirable for healthy cells,
such as those in the intestines, leading to increased incidence
of acute toxicity in this organ.7
The group receiving adjuvant radiotherapy was also
observed to show a high rate of grade 3 intestinal toxicity
(no grade 4 reactions were recorded) both in cervical can-
cer patients (7.9%) and endometrial cancer patients (8.9%).
Severe reactions during radiotherapy in the range of 3–5% have
been observed by many  authors.15–22 It seems that the rate of
grade 3 toxicity obtained in this study may have also been
related to the application of the EORTC/RTOG scale. Accord-
ing to this scale, gastrointestinal toxicity is classiﬁed as grade
3 whenever parenteral hydration is required. Many  patients,
especially older ones, were given intravenous hydration, often
longer than 24 h, for persisting diarrhoea.The analysis of the rate of early toxicity in the bladder
showed no signiﬁcant differences in the incidence of compli-
cations between RT and RCHT patients. Similar results were
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eported by NCIC,14 RTOG 90-0111 and Green’s metaanalysis.23
owever, we  observed more  late reactions in patients receiv-
ng radiochemotherapy than radiotherapy alone. This may
ave been related to the use of cisplatin affecting the urinary
ystem.
Of note, however, is early bladder radiation toxicity found
n high percentage of postoperative cervical cancer patients.
his in turn may have been associated with a larger scope of
urgery as compared to endometrial cancer patients. Radia-
ion toxicity may have also been intensiﬁed by surgery side
ffects, such as bladder dysfunction or infections in the lower
art of the urinary system.6,24–26,12,27,34
A note should be taken that total radiation doses in
atients treated with adjuvant radiotherapy were lower than
n patients treated with radiotherapy alone. But the size of
ose is only one of the factors determining the occurrence
f radiation toxicity, aside from those commonly recognised,
uch as age, metabolic diseases, chronic gastrointestinal or
rinary. The combination of external-beam radiotherapy and
ntravaginal brachytherapy increases the rate of both early and
ate radiation effects.25,28–32
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